NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately.

Dr. Coric successfully led Biohaven through the FDA approval and launch of Nurtec ODT for the treatment of migraine. Under his leadership, the company also filed an NDA for its second drug candidate, ...

Pfizer's growth is boosted by Nurtec ODT, acquired from Biohaven and Padcev from the Seagen acquisition. By 2030, Pfizer aims to add $25 billion to its top line. Pfizer has already boosted its ...

Dr. Coric successfully led Biohaven through the FDA approval and launch of Nurtec ODT for the treatment of migraine. Under his leadership, the company also filed an NDA for its second drug ...

Dr. Coric's background includes leading Biohaven to the successful FDA approval and market launch of Nurtec ODT for migraine treatment, as well as the progression of a second drug candidate ...

Thanks in part to several acquisitions, it has multiple new growth drivers in its lineup, including migraine therapy Nurtec ODT (gained through its 2022 acquisition of Biohaven Pharmaceutical ...

When he was playing baseball for his high school in Idaho, Dean Herkenrath saw his teammates slip little nicotine pouches in their gums in the dugout. It was not uncommon for athletes, from high ...

The company has several newer products with fast-growing sales, notably including migraine therapy Nurtec ODT and cancer drugs Adcetris and Padcev. Pfizer's pipeline features 32 programs in late ...

Although the company will lose patent exclusivity for several top drugs, it also has newer products on the market, such as cancer therapies Adcetris and Padcev along with migraine drug Nurtec ODT ...

Thanks in part to several acquisitions, it has multiple new growth drivers in its lineup, including migraine therapy Nurtec ODT (gained through its 2022 acquisition of Biohaven Pharmaceutical ...

The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the ...